Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teneligliptin and Atorvastatin DDI Study
NCT03769870Phase 1Completed
- Sponsor
- Handok
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of teneligliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Handok. Primary endpoints: Maximum concentration at steady state at 24 hours and Area under the concentration-time curve at steady state at 24 hours. Started Jan 2019; status: completed.
02
Drugs
teneligliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03769870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769870.